23Andme Holding Co. - notizie pubblicate 216 - letture 5.281
23ANDME HOLDING CO.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
23ANDME HOLDING CO.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
23ANDME HOLDING CO.
23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel
23andme and nightingale health announce strategic collaboration to pilot blood biomarker panel june 28, 2024 south san francisco, calif., june 28, 2024 (globe newswire) -- 23andme ...
23ANDME HOLDING CO.
Preliminary Proxy Statement - Form PRE 14A
Table of contents united states securities and exchange commission washington, d.c. 20549 schedule 14a information proxy statement pursuant to section 14(a) of the securities excha ...
23ANDME HOLDING CO.
Regulation FD Presentation Form 8 K
The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer 23andme holding co. ...
23ANDME HOLDING CO.
23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community
23andme and the colorectal cancer alliance collaborate to help advance colorectal cancer research in the black community june 4, 2024 study aims to fill research gap and empower pe ...
23ANDME HOLDING CO.
23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting
23andme therapeutics announces positive preliminary phase 2 safety and efficacy results for 23me-00610, targeting cd200r1, at the 2024 asco annual meeting june 3, 2024 23me-00610mo ...
23ANDME HOLDING CO.
23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting - Form 8-K
23andme therapeutics announces positive preliminary phase 2 safety and efficacy results for 23me-00610, targeting cd200r1, at the 2024 asco annual meeting • 23me-00610 monotherap ...
23ANDME HOLDING CO.
Annual Report for Fiscal Year Ending March 31, 2024 (Form 10-K)
Me-20240331 table of contents united states securities and exchange commission washington, d.c. 20549 form 10-k ______________________________________________ (mark one) ☒ annual ...
23ANDME HOLDING CO.
Management Change/Compensation - Form 8-K
Item 5.02. departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers. as previously disclose ...
23ANDME HOLDING CO.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
23ANDME HOLDING CO.
23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer 23andme holding co. ...
23ANDME HOLDING CO.
23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results - Form 8-K
23andme reports fourth quarter and full year fiscal 2024 financial results south san francisco, calif., may 23, 2024-- 23andme holding co. (nasdaq: me), a leading human genetics an ...
23ANDME HOLDING CO.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
23ANDME HOLDING CO.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
Per i consulenti finanziari
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti